The federal agencies announced the availability of additional doses of nirsevimab-alip (Beyfortus; Sanofi) for infants at high-risk of infection.
The Centers for Disease Control and Prevention (CDC), along with the FDA, have announced the availability of more than 77,000 doses of nirsevimab-alip (Beyfortus; Sanofi), which are being immediately distrusted to hospitals and physicians through the Vaccines for Children Program, as well as through commercial channels.
Nirsevimab-alip is monoclonal antibody approved by the FDA to protect infants against severe respiratory syncytial virus (RSV).
“Helping to ensure the availability of this preventative option to reduce the impact of RSV disease on eligible babies and young children, families and the health care system remains a priority,” said Patrizia Cavazzoni, MD, director of the FDA’s Center for Drug Evaluation and Research, in a press release. “We will continue to use all our regulatory tools to help bring safe, effective and high-quality medicines to the public.”
The federal agencies said that they will continue to work closely with manufactures to maintain the availability of the vaccines through the ends of 2023 and early 2024 to meet the demand during the RSV season.
The CDC and FDA are also working with the American College of Obstetricians and Gynecologists, to encourage health care providers to use the RSV maternal vaccine. This immunization can help safeguard infants against RSV prior to birth.
Additionally, the CDC has been urging clinicians to administer the infant vaccine to patients at the highest risk of infection during this shortage period, including infants up to 6 months, as well as American Indian and Alaska Native infants.
“CDC and FDA are committed to expanding access to this important immunization so that more parents have peace of mind during the winter virus season,” said Nirav D. Shah, MD, JD, CDC’s principal deputy director.
This article was initially published by our sister publication Contemporary Pediatrics.
Reference:
CDC and FDA Expedite the Availability of Additional Doses of New RSV Immunization for Infants. CDC. November 17, 2023. Accessed November 17, 2023. https://www.cdc.gov/media/releases/2023/p1116-rsv-doses.html
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
The benefits of concurrent fetal and maternal heart rate monitoring
April 15th 2024A recent study revealed that employing maternal heart rate monitoring alongside fetal heart rate monitoring during labor significantly decreases the incidence of neonatal encephalopathy and severe neonatal acidemia.
Read More
How vitamin C intake in pregnant smokers impacts offspring airway function trajectory
April 12th 2024Investigating the impact of prenatal vitamin C supplementation on lung function and wheeze occurrence in offspring of pregnant smokers, revealing insights into mitigating respiratory risks.
Read More